Literature DB >> 24239175

High CXCR4 and low VLA-4 expression predicts poor survival in adults with acute lymphoblastic leukemia.

Sun-Young Ko1, Chan-Jeoung Park2, Sang-Hyuk Park3, Young-Uk Cho3, Seongsoo Jang3, Eul-Ju Seo3, Nayoung Kim4, Dae-Young Kim5, Kyung Nam Koh6, Ho Joon Im6, Jong-Jin Seo6, Hyun-Sook Chi3.   

Abstract

Data regarding the prognostic significance of CXCR4 and VLA-4 in ALL are limited. Especially, VLA-4 has not been evaluated at the time of diagnosis in both adult and childhood ALL patients. We prospectively analyzed the expression of VLA-4 and CXCR4 in 54 patients (VLA-4 in 29 adults and 25 children and CXCR4 in 22 adults and 24 children) newly diagnosed with ALL by flow cytometry. Expression levels of VLA-4 and CXCR4 were not different between adults and children with ALL. High CXCR4 and low VLA-4 expression each correlated with worse prognosis in adults; patients with high CXCR4 expression had shorter disease-free survival (p=0.01) and overall survival (p=0.04) and patients with low VLA-4 expression had shorter disease-free survival (p=0.02). Expression levels of CXCR4 and VLA-4 did not predict patient prognosis in children. Analysis of CXCR4 and VLA-4 expression at diagnosis in adults with ALL can provide useful information on patient prognosis.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute lymphoblastic leukemia; Adult; CXCR4; Prognostic marker; Survival; VLA-4

Mesh:

Substances:

Year:  2013        PMID: 24239175     DOI: 10.1016/j.leukres.2013.10.016

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  13 in total

Review 1.  The intricate role of CXCR4 in cancer.

Authors:  Samit Chatterjee; Babak Behnam Azad; Sridhar Nimmagadda
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

Review 2.  Role of CXCR4 in the progression and therapy of acute leukaemia.

Authors:  Long Su; Zheng Hu; Yong-Guang Yang
Journal:  Cell Prolif       Date:  2021-05-29       Impact factor: 6.831

3.  Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.

Authors:  Jiayu Chen; Zijun Y Xu-Monette; Lijuan Deng; Qi Shen; Ganiraju C Manyam; Azahara Martinez-Lopez; Li Zhang; Santiago Montes-Moreno; Carlo Visco; Alexandar Tzankov; Lihui Yin; Karen Dybkaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Xiaoying Zhao; Michael B Møller; John P Farnen; Jane N Winter; Miguel A Piris; Lan Pham; Ken H Young
Journal:  Oncotarget       Date:  2015-03-20

Review 4.  Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison.

Authors:  Rimas J Orentas; Jessica Nordlund; Jianbin He; Sivasish Sindiri; Crystal Mackall; Terry J Fry; Javed Khan
Journal:  Front Oncol       Date:  2014-06-10       Impact factor: 6.244

5.  Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging.

Authors:  Hans Jürgen Wester; Ulrich Keller; Margret Schottelius; Ambros Beer; Kathrin Philipp-Abbrederis; Frauke Hoffmann; Jakub Šimeček; Carlos Gerngross; Michael Lassmann; Ken Herrmann; Natalia Pellegata; Martina Rudelius; Horst Kessler; Markus Schwaiger
Journal:  Theranostics       Date:  2015-03-01       Impact factor: 11.556

6.  Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma.

Authors:  Guillemette Fouquet; Stéphanie Guidez; Valentine Richez; Anne-Marie Stoppa; Christophe Le Tourneau; Margaret Macro; Cécile Gruchet; Arthur Bobin; Niels Moya; Thomas Syshenko; Florence Sabirou; Anthony Levy; Paul Franques; Hélène Gardeney; Lionel Karlin; Lotfi Benboubker; Monia Ouali; Jean-Claude Vedovato; Pierre Ferre; Mariya Pavlyuk; Michel Attal; Thierry Facon; Xavier Leleu
Journal:  Oncotarget       Date:  2018-05-08

7.  G9a Correlates with VLA-4 Integrin and Influences the Migration of Childhood Acute Lymphoblastic Leukemia Cells.

Authors:  Elena Madrazo; David Ruano; Lorea Abad; Estefanía Alonso-Gómez; Carmen Sánchez-Valdepeñas; África González-Murillo; Manuel Ramírez; Javier Redondo-Muñoz
Journal:  Cancers (Basel)       Date:  2018-09-12       Impact factor: 6.639

Review 8.  Role of Hedgehog Signaling in Breast Cancer: Pathogenesis and Therapeutics.

Authors:  Natalia A Riobo-Del Galdo; Ángela Lara Montero; Eva V Wertheimer
Journal:  Cells       Date:  2019-04-25       Impact factor: 6.600

9.  Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies.

Authors:  Sheng-Bin Peng; Xiaoyi Zhang; Donald Paul; Lisa M Kays; Ming Ye; Peter Vaillancourt; Michele Dowless; Louis F Stancato; Julie Stewart; Mark T Uhlik; Haiyan Long; Shaoyou Chu; Victor H Obungu
Journal:  PLoS One       Date:  2016-03-08       Impact factor: 3.240

10.  GLI1 orchestrates CXCR4/CXCR7 signaling to enhance migration and metastasis of breast cancer cells.

Authors:  Shingo Inaguma; Miho Riku; Hideaki Ito; Takumi Tsunoda; Hiroshi Ikeda; Kenji Kasai
Journal:  Oncotarget       Date:  2015-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.